Compare Illumina, Inc. (ILMN) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Oscar Health Inc — how do they compare? Illumina, Inc. trades at $278.17 (market cap $39.95B), while Oscar Health Inc trades at $33.37 (market cap $10.22B). The key difference: Illumina, Inc. is far larger — about 3.9× Oscar Health Inc's market cap, and Oscar Health Inc is more actively traded (4,123,394 versus 3,169,503). Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Oscar Health Inc for 15 Days on average.
| ILMN | OSCR | |
|---|---|---|
Market Cap | $39.95B | $10.22B |
Volume | 3,169,503 | 4,123,394 |
Sector | Health | Health |
52-Week High | $293.69 | $33.81 |
52-Week Low | $91.00 | $10.85 |
Typical Hold Time | 83 Days | 15 Days |
Enterprise Value | $41.31B | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $278.17, up 3.89% today and near its 52-week high of $278.99. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent inclusion in the S&P 500 and positive analyst upgrades reflect growing institutional confidence. Revenue remains stable at $4.34B for 2025 with improved profitability, delivering $850M net income after previous losses.
The outlook remains positive with sequencing growth and AI initiatives driving momentum, though elevated valuation ratios and China market headwinds present risks. Analyst consensus leans bullish with 54% buy ratings, but the current price exceeds the $241 consensus target, suggesting near-term consolidation potential before further upside.
OSCR trades at $33.37, up 1.4% with strong technical momentum and bullish moving averages. The company shows impressive revenue growth from $11.7B in 2025 to $15.3B in 2026, turning profitable with $551M net income. Recent Q1 and Q2 2026 earnings beat expectations, while analyst consensus leans toward Hold (61.54%) with a $34 price target. Technical indicators show bullish signals but RSI suggests potential overbought conditions near-term.
Outlook remains positive with scalable ACA market growth and margin expansion driving earnings potential. Key risks include rising medical costs threatening profitability and competitive pressures. The stock offers growth exposure but requires monitoring of execution on 2029 EPS targets of $4+ and medical loss ratio management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
